那不勒斯预后评分对小细胞肺癌患者的预后价值-现代医学

那不勒斯预后评分对小细胞肺癌患者的预后价值

单位：川北医学院附属医院呼吸与危重症医学科, 四川南充 637000

分类号：R734.2

出版年·卷·期（页码）：2025·53·第四期（639-646）

摘要：

目的： 探讨那不勒斯预后评分(NPS)对小细胞肺癌(SCLC)患者的预后价值。方法： 回顾性分析2017年1月至2022年1月收治的206例SCLC患者的临床资料。根据NPS将患者分为低危组(NPS=0分)、中危组(NPS=1～2分)和高危组(NPS=3～4分)，对3组患者的临床资料进行比较与分析。绘制受试者工作特征(ROC)曲线并计算曲线下面积(AUC)，比较NPS与预后营养指数(PNI)、血小板/淋巴细胞比值(PLR)对生存预后的价值。利用Cox回归分析和Kaplan-Meier (K-M)曲线分析患者的生存数据，比较NPS对无进展生存期(PFS)和总生存期(OS)的影响。结果： 根据治疗前NPS结果，低危组纳入35例患者，中危组纳入92例患者，高危组纳入79例患者。ROC曲线表明，NPS在预后方面优于其他炎症评分(AUC=0.726)。K-M曲线显示，NPS与小细胞肺癌(SCLC)患者的无进展生存期(PFS)和总生存期(OS)之间存在显著相关性(P<0.001)，高危组SCLC患者预后更差(P<0.001)。结论： 那不勒斯预后评分(NPS)在小细胞肺癌(SCLC)患者的预后中有较好的预测价值，该评分的预测价值优于其他营养及炎症指标，NPS高危组的患者预后相对较差。

Objective: To investigate the prognostic value of Naples prognostic score(NPS) in patients with small cell lung cancer(SCLC). Methods: The clinical data of 206 patients with SCLC admitted from January 2017 to January 2022 were retrospectively analyzed. Based on the NPS, the patients were divided into low-risk group(NPS=0 point), intermediate-risk group(NPS=1-2 points) and high-risk group(NPS=3-4 points). The clinical date of the three groups were compared. Receiver operating characteristic(ROC) curves were plotted, and the area under the curve(AUC) was calculated to compare the prognostic value of NPS with that of the prognostic nutritional index(PNI) and platelet-to-lymphocyte ratio(PLR) for survival outcomes. Cox regression analysis and Kaplan-Meier(K-M) curves were used to analyze patient survival data and compare the effect of NPS on progression-free survival(PFS) and overall survival(OS). Results: According to the NPS results of pretreatment, 35 patients were categorized in low-risk group, 92 patients in intermediate-risk group, and 79 patients in high-risk group. The ROC curves showed that NPS was superior to other inflammatory scores in terms of prognosis(AUC=0.726). The K-M curves demonstrated a significant correlation between the NPS and both PFS and OS in patients with SCLC(P<0.001). Patients in the high-risk group had a worse prognosis compared to other groups(P<0.001). Conclusion: The NPS shows significant predictive value for the prognosis of patients with SCLC, outperforming other nutritional and inflammatory indicators. Patients in the high-risk NPS group have a relatively poorer prognosis.

参考文献：

[1] THAI A A,SOLOMON B J,SEQUIST L V,et al.Lung cancer[J].Lancet,2021,398(10299):535-554.
[2] 王新,墙建军.小细胞肺癌发生和预后相关血清外泌体分子标记物的鉴定和验证[J].现代医学,2023,51(1):31-37.
[3] MEIJER J J,LEONETTI A,AIRÒ G,et al.Small cell lung cancer:novel treatments beyond immunotherapy[J].Semin Cancer Biol,2022,86(P2):376-385.
[4] GEORGE J,LIM J S,JANG S J,et al.Comprehensive genomic profiles of small cell lung cancer[J].Nature,2015,524(7563):47-53.
[5] GUO D,JING W,ZHU H,et al.Clinical value of carcinoembryonic antigen for predicting the incidence of brain metastases and survival in small cell lung cancer patients treated with prophylactic cranial irradiation[J].Cancer Manag Res,2018,10:3199-3205.
[6] STRATIGOS M,MATIKAS A,VOUTSINA A,et al.Targeting angiogenesis in small cell lung cancer[J].Transl Lung Cancer Res,2016,5(4):389-400.
[7] TSOUKALAS N,ARAVANTINOU-FATOROU E,BAXEVANOS P,et al.Advanced small cell lung cancer(SCLC):new challenges and new expectations[J].Ann Transl Med,2018,6(8):145.
[8] BIRIM O,KAPPETEIN A P,VAN KLAVEREN R J,et al.Prognostic factors in non-small cell lung cancer surgery[J].Eur J Surg Oncol,2006,32(1):12-23.
[9] KAWAGUCHI T,TAKADA M,KUBO A,et al.Gender,histology,and time of diagnosis are important factors for prognosis:analysis of 1 499 never-smokers with advanced non-small cell lung cancer in Japan[J].J Thorac Oncol,2010,5(7):1011-1017.
[10] LA FLEUR L,BOTLING J,HE F,et al.Targeting MARCO and IL37R on immunosuppressive macrophages in lung cancer blocks regulatory T cells and supports cytotoxic lymphocyte function[J].Cancer Res,2021;81(4):956-967.
[11] DENG T B,ZHANG J,ZHOU Y Z,et al.The prognostic value of C-reactive protein to albumin ratio in patients with lung cancer[J].Medicine,2018,97(50):e13505.
[12] GALIZIA G,LIETO E,AURICCHIO A,et al.Naples prognostic score,based on nutritional and inflammatory status,is an independent predictor of long-term outcome in patients undergoing surgery for colorectal cancer[J].Dis Colon Rectum,2017,60(12):1273-1284.
[13] NAKAGAWA N,YAMADA S,SONOHARA F,et al.Clinical implications of naples prognostic score in patients with resected pancreatic cancer[J].Ann Surg Oncol,2020,27(3):887-895.
[14] LI Q,CONG R,WANG Y,et al.Naples prognostic score is an independent prognostic factor in patients with operable endometrial cancer:results from a retrospective cohort study[J].Gynecol Oncol,2021,160(1):91-98.
[15] KANO K,YAMADA T,YAMAMOTO K,et al.The impact of pretherapeutic naples prognostic score on survival in patients with locally advanced esophageal cancer[J].Ann Surg Oncol,2021,28(8):4530-4539.
[16] HUANG X,HU H,ZHANG W,et al.Prognostic value of prognostic nutritional index and systemic immune-inflammation index in patients with osteosarcoma[J].J Cell Physiol,2019,234(10):18408-18414.
[17] LEI J,WANG Y,GUO X,et al.Low preoperative serum ALB level is independently associated with poor overall survival in endometrial cancer patients[J].Future Oncol,2020,16(8):307-316.
[18] MANDAL C C,RAHMAN M M.Targeting intracellular cholesterol is a novel therapeutic strategy for cancer treatment[J].J Cancer Sci Ther,2014,6(12):510-513.
[19] WANG D,DUBOIS R N.Immunosuppression associated with chronic inflammation in the tumor microenvironment[J].Carcinogenesis,2015,36(10):1085-93.
[20] BREMNES R M,AL-SHIBLI K,DONNEM T,et al.The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development,progression,and prognosis:emphasis on non-small cell lung cancer[J].J Thorac Oncol,2011,6(4):824-833.
[21] OSTRAND-ROSENBERG S.Inflammation,immune suppression,and tumor progression[J].BMC Proc,2013,7 Suppl 2(Suppl 2):K20.
[22] POWELL D R,HUTTENLOCHER A.Neutrophils in the tumor microenvironment[J].Trends Immunol,2016,37(1):41-52.
[23] MOHME M,RIETHDORF S,PANTEL K.Circulating and disseminated tumour cells-mechanisms of immune surveillance and escape[J].Nat Rev Clin Oncol,2017,14(3):155-167.
[24] GU H,HUANG T,SHEN Y,et al.Reactive oxygen species-mediated tumor microenvironment transformation:the mechanism of radioresistant gastric cancer[J].Oxid Med Cell Longev,2018,2018:5801209.
[25] VELAEI K,SAMADI N,BARAZVAN B,et al.Tumor microenvironment-mediated chemoresistance in breast cancer[J].Breast,2016,30:92-100.
[26] KITAMURA T,QIAN B Z,Pollard J W.Immune cell promotion of metastasis[J].Nat Rev Immunol,2015,15(2):73-86.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录